News
Valneva said it has been supplying Ixchiq to help the French government respond to a major outbreak of chikungunya in La ...
Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular ...
AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the ...
Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 ...
Anyone who purports to care about global health, about public health, should be speaking out against these actions, loudly ...
The NEJM has fired back a response to the Department of Justice (DoJ) asserting its "commitment to evidence-based ...
Pharmaceutical Social Media: Engage Compliantly & Drive Results! Customer-Centric & Balanced Risk/Reward Approaches To Boost Profits & Compliantly Engage, Influence & Target Patients & HCPs With ...
Novartis is putting $20 million upfront into a near-$1 billion deal with US start-up Lindy Biosciences that aims to convert biologic drugs delivered by infusion into therapies that can be self ...
The social media landscape is shifting. As X becomes a battleground for increasingly polarised debate, its lesser-known (but strikingly similar) cousin is rapidly gaining traction. A year on from ...
Lawyers for Todd Engel, 62, filed suit yesterday in New Jersey superior court. According to the complaint, Engel is now ...
As the pharmaceutical industry continues to push the boundaries of innovation, the role of digital solutions like eCOA platforms will only grow in significance. For rare disease trials, where patient ...
Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results